Below is a press release dated today (3/10/22) from Abivax:
The Quick Basics
Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have now reached the first year of treatment and all achieved at least an ACR201, with 19 and 12 patients achieving ACR50 and ACR70 respectively.
Long-term safety profile (50mg ABX464 once daily + MTX) favorable and consistent with previous observations.
The induction and maintenance results support further clinical development of ABX464 in RA and potentially other rheumatology indications.
The clinical induction and maintenance data in ulcerative colitis and rheumatoid arthritis underpin the potential of ABX464 to address a broad range of chronic inflammatory diseases.
In G7 countries, the market for ulcerative colitis, Crohn’s disease and rheumatoid arthritis is expected to grow to approximately USD 50B in 2026.
The Full Press Release
Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports promising results from its phase 2a maintenance trial in rheumatoid arthritis (RA) after one year of continued daily treatment with 50mg ABX464.